Detrimental platelet activation is a hallmark feature across the spectrum of thromboemblic events. Thus, antiplatelet therapies have become a key therapeutic option for prevention of thromboembolism and its consequences. However, there remains considerable uncertainty regarding how to optimize antithrombotic effects while minimizing bleeding risk. There are also questions about which antiplatelet therapy is most appropriate for patients with various presentations of atherothrombotic disease. Physicians who treat patients with thromboembolic conditions need to keep abreast of the latest antithrombotic/antiplatelet clinical trial results to ensure optimal outcomes for their patients.
This highly interactive half-day meeting will provide a unique learning experience by offering a combination of interactive activities, case-based presentations, and applications of guideline-based management strategies. Participants will become more competent in managing their ACS patients, selecting appropriate antiplatelet options, and minimizing bleeding risk. |